Literature DB >> 28949031

Cumulative evidence for relationships between multiple variants in the VTI1A and TCF7L2 genes and cancer incidence.

Min Zhang1, Mingshuang Tang1, Yanfei Fang1,2, Huijie Cui1, Siyu Chen1, Junlong Li2, Hongyan Xiong2, Jiachun Lu3, Dongqing Gu1,2, Ben Zhang1,2,3,4.   

Abstract

Genetic studies have linked the VTI1A-TCF7L2 region with risk of multiple cancers. However, findings from these studies were generally inconclusive. We aimed to provide a synopsis of current understanding of associations between variants in the VTI1A-TCF7L2 region and cancer susceptibility. We conducted a comprehensive research synopsis and meta-analysis to evaluate associations between 17 variants in this region and risk of seven cancers using data from 32 eligible articles totaling 224,656 cancer cases and 324,845 controls. We graded cumulative evidence of significant associations using Venice criteria and false-positive report probability tests. We also conducted analyses to evaluate potential function of these variants using data from the Encyclopedia of DNA Elements (ENCODE) Project. Eight variants showed a nominally significant association with risk of individual cancer (p < 0.05). Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10-5 ] and rs7904519 (OR = 1.07, p = 2.02 × 10-14 ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10-16 ), rs12241008 (OR = 1.13, p = 1.36 × 10-10 ) and rs10506868 (OR = 1.10, p = 3.98 × 10-9 ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10-18 ) and rs11196067 (OR = 1.18, p = 3.59 × 10-13 ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10-4 ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer. Data from ENCODE suggested that seven variants with strong evidence and other correlated variants might fall within putative functional regions. Collectively, our study provides summary evidence that common variants in the VTI1A and TCF7L2 genes are associated with risk of breast, colorectal, lung cancer and glioma and highlights the significant role of the VTI1A-TCF7L2 region in the pathogenesis of human cancers.
© 2017 UICC.

Entities:  

Keywords:  TCF7L2; VTI1A; cancer; genetic variant; susceptibility

Mesh:

Substances:

Year:  2017        PMID: 28949031     DOI: 10.1002/ijc.31074

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

Review 1.  The Role of Vti1a in Biological Functions and Its Possible Role in Nervous System Disorders.

Authors:  Fajuan Tang; Jiali Fan; Xiaoyan Zhang; Zhuan Zou; Dongqiong Xiao; Xihong Li
Journal:  Front Mol Neurosci       Date:  2022-05-27       Impact factor: 6.261

2.  Silencing TCF4 Sensitizes Melanoma Cells to Vemurafenib Through Inhibiting GLUT3-Mediated Glycolysis.

Authors:  Can Liu; Siqi He; Jianfei Zhang; Shiyan Li; Jian Chen; Chaofei Han
Journal:  Onco Targets Ther       Date:  2020-05-29       Impact factor: 4.147

3.  Association of TCF7L2, CASC8 and GREM1 Polymorphisms in Patients with Colorectal Cancer and Type II Diabetes Mellitus.

Authors:  Anca Florentina Mitroi; Nicoleta Leopa; Eugen Dumitru; Costel Brînzan; Cristina Tocia; Andrei Dumitru; Răzvan Cătălin Popescu
Journal:  Genes (Basel)       Date:  2022-07-22       Impact factor: 4.141

4.  Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.

Authors:  Toru Shigeoka; Takashi Nomiyama; Takako Kawanami; Yuriko Hamaguchi; Tsuyoshi Horikawa; Tomoko Tanaka; Shinichiro Irie; Ryoko Motonaga; Nobuya Hamanoue; Makito Tanabe; Kazuki Nabeshima; Masatoshi Tanaka; Toshihiko Yanase; Daiji Kawanami
Journal:  J Diabetes Investig       Date:  2020-04-09       Impact factor: 4.232

5.  Expression of TCF7L2 in Glioma and Its Relationship With Clinicopathological Characteristics and Patient Overall Survival.

Authors:  Shiyuan Jing; Lei Chen; Song Han; Ning Liu; MingYang Han; Yakun Yang; Changxiang Yan
Journal:  Front Neurol       Date:  2021-07-08       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.